# Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

> **NCT00346684** · PHASE2 · COMPLETED · sponsor: **University of Cologne**

## Conditions studied

- Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00346684
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00346684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00346684, "Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00346684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*